Clinical trial · Interventional
Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study
Impact Advanced Recovery® for Radical Cystectomy (RC) Patients
NCT01868087CI-TRIAL-00108412completedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is determine if using Impact Advanced Recovery® before and after RC surgery helps reduce surgical complications.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Radical Cystectomy | — | UNRESOLVED | — |
| Surgery | — | UNRESOLVED | — |
| Urinary Bladder Neoplasms | Bladder Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Boost Plus® | Dietary Supplement | — | UNRESOLVED |
| Impact Advanced Recovery® | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Impact Advanced Recovery®
- description
- 3 briks daily (240 mL per brik) of Impact Advanced Recovery® to be take for 5 days before and after RC surgery
- interventionNames
- Dietary Supplement: Impact Advanced Recovery®
- type
- PLACEBO_COMPARATOR
- label
- Boost Plus®
- description
- 3 briks daily (240 mL per brik) of Boost Plus® to be take for 5 days before and after RC surgery
- interventionNames
- Dietary Supplement: Boost Plus®
Primary outcomes (1)
- measure
- Immune and Inflammation Response
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 40 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Men undergoing RC surgery for primary bladder cancer Exclusion Criteria: * Patients with swallowing difficulties or unable to tolerate oral intake * Evidence of metastatic disease * Weight loss ≥ 10% (with respect to usual body weight) in the 6 months prior to surgery or BMI ≤ 18.5 * Patients undergoing cystectomy for non-bladder primary malignancy or cancer type other than urothelial * Active viral infections such as Human immunodeficiency virus (HIV) positive, hepatitis, or who have a known immunodeficient state * Prior history of gouty arthritis or uric acid stones * Patients with milk, soy, or fish allergies
References
Publications (1)
- RESULTHamilton-Reeves JM, Bechtel MD, Hand LK, Schleper A, Yankee TM, Chalise P, Lee EK, Mirza M, Wyre H, Griffin J, Holzbeierlein JM. Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial. Eur Urol. 2016 Mar;69(3):389-92. doi: 10.1016/j.eururo.2015.11.019. Epub 2015 Nov 30. PMID 26654125